. Author manuscript; available in PMC: 2018 Sep 1.

Published in final edited form as: Curr Opin Rheumatol. 2017 Sep;29(5):458–466. doi: 10.1097/BOR.0000000000000410

Table 2.

Summary of efficacy and mechanisms by which adjuvant therapeutics could potentially benefit APS patients

		Hydroxychloroquine	Statins	Rivaroxaban
Summary of efficacy:
Thrombotic risk	Mouse models	Protects [9,10]	Protects [11]
Thrombotic risk	APS patients	No prospective studies in APS, but protects in post-operative setting [12]	No studies in APS, but protects in the general population [13]	Efficacy may be similar to warfarin (although further study is needed) [14]
Obstetric events	Mouse models	Prevents fetal death and metabolic changes [15]	Prevents fetal death [16]
Obstetric events	APS patients	May prevent pregnancy loss [7,17]	May prevent fetal morbidity and mortality [18]
Potential anti-inflammatory mechanisms:
Complement		Inhibits activation and deposition [15]		Decreases activation [19]
Type I IFN signature		Decreases [20]	Decreases [20]
NET release		Possibly inhibits [21]